Braidwell LP Buys 241,100 Shares of Boston Scientific Corporation $BSX

Key Points

• Braidwell LP increased its Boston Scientific stake by 69.6% in the second quarter, acquiring 241,100 shares and bringing its holdings to 587,567 shares valued at approximately $25.1 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific reported quarterly earnings of $0.86 per share, exceeding estimates of $0.83, while revenue rose 7.5% year over year to $5.44 billion. The company also authorized a $5 billion share-repurchase program, covering up to 6.4% of outstanding shares.
• Company insiders purchased approximately $9.4 million of stock during the latest quarter, including significant buys by CEO Michael Mahoney and director Edward Ludwig. Analysts maintain a “Moderate Buy” consensus with an average price target of $71.62, compared with a recent share price near $48.40.

Braidwell LP lifted its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 69.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 587,567 shares of the medical equipment provider's stock after acquiring an additional 241,100 shares during the period. Braidwell LP's holdings in Boston Scientific were worth $25,077,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of BSX. Kelleher Financial Advisors acquired a new stake in Boston Scientific in the second quarter worth $25,000. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the second quarter worth $26,000. Swiss RE Ltd. acquired a new position in shares of Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC acquired a new position in shares of Boston Scientific in the 4th quarter valued at $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Boston Scientific in the 1st quarter valued at $28,000. Institutional investors own 89.07% of the company's stock.

Insiders Place Their Bets

In other Boston Scientific news, Director Edward J. Ludwig acquired 5,000 shares of the business's stock in a transaction dated Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney bought 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares of the company's stock, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 194,522 shares of company stock valued at $9,385,210 in the last quarter. 0.34% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

BSX opened at $48.40 on Thursday. The company has a market capitalization of $70.14 billion, a price-to-earnings ratio of 19.59, a P/E/G ratio of 1.11 and a beta of 0.57. The business's 50-day moving average price is $46.77 and its two-hundred day moving average price is $55.99. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board of directors believes its stock is undervalued.

Analysts Set New Price Targets

Several analysts recently commented on the company. Leerink Partners set a $60.00 price objective on Boston Scientific in a research note on Thursday, July 30th. Stifel Nicolaus set a $60.00 price target on Boston Scientific in a report on Wednesday, July 29th. Wolfe Research lowered Boston Scientific from an "outperform" rating to a "peer perform" rating in a research report on Friday, May 29th. Argus reiterated a "hold" rating on shares of Boston Scientific in a research report on Friday, July 31st. Finally, The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a research note on Thursday, May 28th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source